本文選題：絕經(jīng)后骨質(zhì)疏松癥 + 唑來膦酸��； 參考：《浙江大學(xué)》2017年碩士論文

【摘要】：目的:研究分析使用唑來膦酸治療66例絕經(jīng)后女性骨質(zhì)疏松癥患者的臨床療效。方法:選擇2012-2016年間在我院骨科住院行靜脈滴注唑來膦酸治療的絕經(jīng)后女性骨質(zhì)疏松癥患者共66例,年齡范圍51-97歲,平均(68.606±8.621)歲�；颊呤褂眠騺盱⑺�(密固達(dá))5mg(100ml)靜脈滴注1次,滴注時間15min以上,并且患者每天基礎(chǔ)服用骨礦化促進(jìn)藥物骨化三醇0.5μg/d及碳酸鈣片1片/天。在使用唑來膦酸治療前、治療1年后分別檢測患者腰椎總骨密度、右側(cè)髖關(guān)節(jié)骨密度,以及血清總Ⅰ型膠原氨基酸延長肽(t-P11NP)、N端骨鈣素(N-MID)、β-膠原特殊序列(β-CTX)、25-羥基維生素D(25-OH-VD)這些骨代謝指標(biāo),并對檢測結(jié)果進(jìn)行統(tǒng)計(jì)分析。比較患者骨密度、血清骨代謝指標(biāo)在治療前后的變化差異,以及在各年齡段(51-60歲,61-70歲,70歲以上)治療前后的差異�！酢踅Y(jié)果:患者腰椎總骨密度、血清總Ⅰ型膠原氨基酸延長肽、N端骨鈣素、β-膠原特殊序列、25-羥基維生素D在治療1年后與治療前相比有顯著差異(P0.05)。全髖關(guān)節(jié)骨密度在治療1年后與治療前比較,雖有所增加,但差異卻無統(tǒng)計(jì)學(xué)意義(P0.05)。51-60歲,61-70歲,70歲以上三個年齡分組中腰椎總骨密度、血清總Ⅰ型膠原氨基酸延長肽、N端骨鈣素、β-膠原特殊序列、25-羥基維生素D在治療1年后與治療前相比均有顯著差異(P0.05)。而右氈關(guān)節(jié)骨密度與治療前比較雖均有增加,但差異無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:靜脈滴注唑來膦酸治療絕經(jīng)后女性骨質(zhì)疏松癥,不僅能有效提高患者腰椎的總骨密度,同時也可改善患者的血清中骨代謝指標(biāo),并且對各年齡段的絕經(jīng)后骨質(zhì)疏松癥女性均有明確的臨床效果。
[Abstract]:Objective: to study the clinical effect of zoledronic acid on 66 postmenopausal women with osteoporosis. Methods: a total of 66 postmenopausal female osteoporosis patients, aged 51-97 years, with an average of 68.606 鹵8.621 years, were selected from 2012 to 2016. The patients were given zoledronic acid (5 mg / 100 ml) intravenously for more than 15min, and the patients were given bone mineralization promoting drug ossification 0.5 渭 g / d and calcium carbonate tablet 1 / day. The total bone mineral density (BMD) of lumbar vertebrae and the bone density of right hip joint were measured before and 1 year after treatment with zoledronic acid. Serum total type I collagen amino acid prolongation peptide (t-P11NPN), N-terminal osteocalcin N-MIDD, 尾 -collagen special sequence (尾 -CTX, 25-hydroxyvitamin D, 25-OH-VD), and the results were analyzed statistically. To compare the changes of bone mineral density (BMD), serum bone metabolism index (BMD) before and after treatment, and the difference before and after treatment (51-60 years old or 61-70 years old or over) before and after treatment. Results: total bone mineral density of lumbar vertebrae, The serum total type I collagen amino acid prolongation peptide N-terminal osteocalcin, 尾 -collagen special sequence 25 hydroxyvitamin D had significant difference after 1 year compared with that before treatment (P 0.05). The bone mineral density of total hip joint increased a year after treatment compared with that before treatment, but there was no significant difference in total lumbar bone mineral density (BMD) of lumbar vertebrae in three age groups of 61-70 years old and over 70 years old, but the difference was not statistically significant. Serum total type I collagen amino acid prolongation peptide N-terminal osteocalcin and 尾 -collagen special sequence 25-hydroxyvitamin D were significantly different after 1 year treatment compared with those before treatment (P 0.05). The bone mineral density (BMD) of right tapetum was higher than that before treatment, but the difference was not statistically significant (P 0.05). Conclusion: intravenous infusion of zoledronic acid in the treatment of postmenopausal female osteoporosis can not only improve the total bone mineral density of lumbar vertebrae, but also improve the bone metabolism index in serum. And there is a clear clinical effect for postmenopausal osteoporosis women of all ages.
【學(xué)位授予單位】：浙江大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R580
，

本文編號：2040602